Docetaxel is under clinical development by Samyang Biopharmaceuticals and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase III drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Docetaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Docetaxel overview
Docetaxel (Nanoxel M) is under development for the treatment of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). It is a semi-synthetic, second-generation taxanes, acts as anti neoplastic agent. It is formulated as solution for intravenous route of administration. It is indicated for the treatment of locally progressed or metastatic breast cancer along with doxorubicin, metastatic prostate cancer, non-small cell lung cancer, gastric cancer, metastatic ovarian cancer, head and neck cancer, esophageal cancer.
It was under development for the treatment of non muscle invasive bladder cancer (NMIBC). It is administered through intravesical route.
Samyang Biopharmaceuticals overview
Samyang Biopharmaceuticals (Samyang Biopharm), a subsidiary of Samyang Holdings Corp, develops pharmaceutical products and medical devices. The company’s pharmaceutical products include anti-cancer drugs, injections, transdermal patches, active pharmaceutical ingredients (APIs), and oncology formulations. It also focuses on the development and commercialization of medical devices such as biodegradable surgical sutures, synthetic absorbable suture materials, partially absorbable lightweight mesh, biodegradable dental implant materials, biosurgery products, and other raw materials. Samyang Biopharm offers its products for the treatment of breast, lung, ovarian, head, and neck cancers. Samyang Biopharm’s key brands include Genexol, Nicostop, Nanoxel, Trisorb, and Monosorb, among others. The company, through its subsidiaries, collaborates with biotechnology, pharmaceutical, venture firms, research institutes, and universities to develop new products and drug delivery technologies. Samyang Biopharm is headquartered in Seongnam, Gyeonggi-do, South Korea.
For a complete picture of Docetaxel’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
